Skip to main content
Figure 2 | Cost Effectiveness and Resource Allocation

Figure 2

From: Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decisionmaking framework to growth hormone for Turner syndrome patients

Figure 2

Intrinsic value estimate for intervention on the MCDA Value Matrix scale and value contribution of each component. *For an intervention to achieve close to 100% on this scale, it would have to cure a severe endemic disease, demonstrate a major improvement in safety, efficacy and PRO compared to limited existing approaches, and result in major healthcare savings. Conversely, an intervention that scores low would be for a rare disease that is not severe, with minimal improvement in efficacy over existing alternatives, with major safety and PRO issues and resulting in major increases in healthcare spending.

Back to article page